Product Description
Mechanisms of Action: OXTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Surgical Wound Infection|Obesity
Phase 2: Obstetric Labor, Premature|Premature Ejaculation|Adenomyosis
Phase 1: Pain Unspecified|Healthy Volunteers|Obstetric Labor, Premature|Premature Ejaculation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MCC-21-18040 | P4 |
Not yet recruiting |
Obesity|Surgical Wound Infection |
2020-08-24 |
|
| NCT02794467 | P2 |
Withdrawn |
Adenomyosis |
2016-10-01 |
|
| Study IVF116828 | P1 |
Terminated |
Healthy Volunteers|Pain Unspecified |
2016-02-07 |
|
| NCT02703181 | P1 |
Completed |
Healthy Volunteers |
2015-09-10 |